Drugs & Aging

, Volume 8, Issue 5, pp 378–400 | Cite as

Intranasal Salcatonin (Salmon Calcitonin)

A Review of its Pharmacological Properties and Role in the Management of Postmenopausal Osteoporosis
  • Greg L. Plosker
  • Donna McTavish
Drug Evaluation

Abstract

Synopsis

Osteoporosis is a common problem among postmenopausal women and is associated with significant morbidity, mortality and costs primarily resulting from osteoporotic fractures.

Salcatonin (salmon calcitonin) inhibits osteoclastic bone resorption and is approximately 40 to 50 times more potent than human calcitonin. In most randomised trials in which intranasal salcatonin (usually 50 to 200 IU/day plus oral calcium supplements) was administered for 1 to 5 years to postmenopausal women for prevention of osteoporosis, bone mineral density or content of the lumbar spine increased by approximately 1 to 3% from baseline. In contrast, postmenopausal women receiving only oral calcium supplements typically had reductions in bone mineral density or content of about 3 to 6%. The difference between treatment groups was statistically significant in essentially all studies. Although changes in bone mineral density or content were broadly similar in studies of postmenopausal women with established osteoporosis to those in postmenopausal women receiving therapy for prevention of the disease, studies in women with established osteoporosis did not usually demonstrate statistically significant differences between treatment groups. Also in postmenopausal women with established osteoporosis, intranasal salcatonin reduced pain and/or analgesic consumption in some trials and, in a limited number of studies of relatively short duration (i.e. ≤2 years), the incidence of osteoporotic fractures. A large multicentre 5-year study with adequate statistical power to confirm the effect of intranasal salcatonin on reducing osteoporotic fracture rates in postmenopausal women is currently under way.

The intranasal formulation of salcatonin offers a more convenient and better tolerated alternative to the parenteral formulation of the drug which is administered by regular subcutaneous or intramuscular injections. Adverse events associated with the intranasal formulation are generally mild and transient, usually involving local reactions such as nasal discomfort, rhinorrhoea or rhinitis.

Thus, for postmenopausal women unable or unwilling to tolerate long term hormone replacement therapy, intranasal salcatonin is an attractive alternative for the management of osteoporosis.

Pharmacodynamic Properties

Salcatonin (salmon calcitonin) is approximately 40 to 50 times more potent than human calcitonin, an endogenous hormone intimately involved in calcium homeostasis. Studies in humans demonstrated that single-dose intranasal administration of salcatonin 50 to 400IU reduced bone resorption and increased urinary excretion of calcium, phosphate and sodium.

The mechanism of action of salcatonin mimics the physiological action of human calcitonin. Inhibition of bone resorption by salcatonin depends on binding of the drug to specific calcitonin receptors on osteoclasts. Once binding occurs, salcatonin reduces the recruitment and activity of these bone-resorbing cells. The effect of salcatonin on bone formation has been shown in experimental models and in clinical trials of postmenopausal women. Putative bone-forming effects may be related, in small part, to a direct anabolic action of the drug on osteoblast-line cells, although further research is needed to clarify this issue.

A number of mechanisms have been suggested to account for the analgesic action of salcatonin in patients with skeletal disorders. These include increased plasma β-endorphin levels, effects on central serotonergic or monoaminergic pathways, modification of intracellular calcium levels in the CNS and, perhaps the most likely mechanism, a direct central effect via specific receptors. The analgesic action appears to be independent of the effect on osteoclastic bone resorption.

Although antibody formation against human calcitonin is rare during long term administration of the hormone, approximately 40 to 70% of patients receiving long term therapy with intranasal or parenteral salcatonin produce antibodies specific for salcatonin. The clinical significance of these antibodies is unclear; however, clinical trials have generally shown sustained long term efficacy of intranasal salcatonin despite specific antibody formation in a significant proportion of postmenopausal women with osteoporosis.

Pharmacokinetic Properties

Peak plasma salcatonin concentrations are achieved 31 to 39 minutes after intra-nasal administration and are dose-related. Although bioavailability of intranasal salcatonin is approximately 3% of that for intramuscular salcatonin, plasma drug concentrations are typically more sustained following intranasal than parenteral administration. The intranasal formulation provides approximately 25 to 50% of the biological activity of the same parenterally administered dose. Salcatonin appears to distribute extensively into extravascular tissue sites. Elimination half-life has been calculated to be 43 minutes.

Therapeutic Use

In most randomised studies in which intranasal salcatonin (usually 50 to 200 IU/day) plus oral calcium supplements were administered for 1 to 5 years to recently postmenopausal women for prevention of osteoporosis, bone mineral density or content of the lumbar spine increased by approximately 1 to 3% from baseline compared with reductions of about 3 to 6% among women receiving oral calcium supplements only. These trials consistently demonstrated statistically significant differences between salcatonin and control treatment groups for changes in vertebral bone mineral density and, in a small number of studies, similar results were shown for changes in forearm bone mineral content. A long term evaluation of a relatively low dose intermittent intranasal salcatonin regimen (50 IU/day for 5 days/week) demonstrated a statistically significant difference in favour of salcatonin plus calcium over calcium alone in bone mineral density of lumbar vertebrae after 6 months which was maintained for the entire duration of the 5-year study. In most trials, attenuation of bone loss by salcatonin was accompanied by reductions in biochemical markers of bone résorption.

Both cyclical regimens of intranasal salcatonin 100 or 200 IU/day (which involved interruption of therapy every other month for 18 months) and continuous administration of the drug at the same dosages (all regimens with oral calcium supplements) increased bone mineral content of the lumbar spine by approximately 4 to 5% from baseline in postmenopausal women with a high rate of bone turnover. Peak increases in bone mineral content occurred somewhat earlier and tended to be slightly higher among women receiving continuous therapy.

In general, intranasal administration of salcatonin produced broadly similar effects on bone mineral density or content in postmenopausal women with established osteoporosis to those in postmenopausal women receiving the drug for prevention of the disease; however, statistically significant differences between treatment groups were usually not demonstrated. Randomised studies in postmenopausal women with established osteoporosis receiving intranasal salcatonin 50, 100 or 200 IU/day for 1 to 2 years have demonstrated a dose-related response with respect to changes in bone mineral density or content. Results of a large 2-year trial comparing intranasal salcatonin 100 IU/day with oral alendronate 10 or 20 mg/day (all with oral calcium supplements) demonstrated a somewhat greater effect of the bisphosphonate than salcatonin on increasing bone mineral density of the lumbar spine in postmenopausal women with established osteoporosis. However, the dosage of intranasal salcatonin used in the trial was only half the recommended dosage, and salcatonin was not administered under a double-blind protocol.

Importantly, both parenteral and intranasal salcatonin have been shown to decrease fracture rates in this patient population, although this has been documented in only a limited number of trials. In a study of 164 elderly postmeno-pausal women with “moderate” osteoporosis, those who received intranasal salcatonin 50, 100 or 200 IU/day plus calcium supplements for 2 years had a statistically significant reduction in fracture rate to approximately one-third that of women who received calcium supplements only. In another randomised study of 88 postmenopausal women with established osteoporosis, cyclical treatment with intranasal salcatonin 100 IU/day plus oral calcium supplements (for 2 consecutive weeks followed by 2 weeks without therapy) for 1 year resulted in a statistically significant reduction in the rate of new vertebral fractures compared with calcium alone. These studies were of relatively short duration, and the effect of long term intranasal salcatonin on osteoporotic fracture rates is currently under investigation in a much larger 5-year study of more than 1200 postmenopausal women. Intranasal salcatonin has also been associated with improvement in pain and/or reductions in analgesic consumption in some studies of postmenopausal women with established osteoporosis.

Tolerability

In general, adverse events associated with intranasal administration of salcatonin are relatively mild and tend to occur in less than 10% of patients. The most frequently reported adverse events are local transient reactions such as stinging or tingling of the nasal passage, sneezing, rhinitis, rhinorrhoea and nasal mucosal erythema which lead to discontinuation of therapy in about 4% of patients. In a comparative trial, primarily in patients with Paget’s disease, 10% of patients receiving subcutaneously administered salcatonin discontinued therapy because of adverse events compared with 4% of those receiving the drug by intranasal administration.

Dosage and Administration

The recommended intranasal dosage of salcatonin for the management of established osteoporosis is 200IU once daily. In clinical trials, postmenopausal women received intranasal salcatonin dosages ranging from 50 to 400 IU/day as a single daily dose or in 2 divided doses for the prevention or treatment of osteoporosis. In virtually all clinical studies with intranasal salcatonin, patients also received oral calcium supplements. It is not clear whether cyclical regimens of intranasal salcatonin plus oral calcium supplements (e.g. 1 month of therapy followed by no drug treatment for 1 month and repeated in a cyclical fashion) have any clinically significant advantages over continuous treatment.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Clissold SP, Fitton A, Chrisp P. Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging. Drugs Aging 1991 Sep-Oct; 1: 405–23PubMedGoogle Scholar
  2. 2.
    McEvoy GK, Litvak K, Welsh Jr OH, et al., editors. American Hospital Formulary Service drug information. Bethesda: American Society of Health-System Pharmacists, Inc., 1995Google Scholar
  3. 3.
    Reynolds JEF, Parfitt K, Parsons AV, et al., editors. Martindale: the extra pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993Google Scholar
  4. 4.
    Azria M, Copp DH, Zanelli JM. 25 Years of salmon calcitonin: from synthesis to therapeutic use. Calcif Tissue Int 1995; 57: 405–8PubMedGoogle Scholar
  5. 5.
    Gnudi S, Zati A, Giardino R, et al. Prevention of post-ovariec-tomy osteoporosis in the rat. Comparative study between salmon calcitonin and aminosuberic analogue of eel calcitonin [in Italian]. Minerva Endocrinol 1993 Sep; 18: 123–7PubMedGoogle Scholar
  6. 6.
    Mosekilde L, Danielsen CC, Gasser J. The effect on vertebral bone mass and strength of long term treatment with anti-resorptive agents (estrogen and calcitonin), human parathyroid hormone- (1–38), and combination therapy, assessed in aged ovariectomized rats. Endocrinology 1994 May; 134: 2126–34PubMedGoogle Scholar
  7. 7.
    Nakamuta H, Sasaki M, Ichikawa M, et al. An acute and focal osteopenia model using ovariectomized rats: a rapid detection of the protective effect of salmon calcitonin. Biol Pharm Bull 1993 Mar; 16: 325–7PubMedGoogle Scholar
  8. 8.
    Nakamuta H, Nitta T, Hoshino T, et al. Nasal salmon calcitonin: evaluation of bioavailability and anti-osteoporotic potency in rats [abstract]. Jpn J Pharmacol 1995; 67 Suppl. 1: 41Google Scholar
  9. 9.
    Lyles KW, Jackson TW, Nesbitt T, et al. Salmon calcitonin reduces vertebral bone loss in glucocorticoid-treated beagles. Am J Physiol 1993 Jun; 264(6 Pt 1): E938–42PubMedGoogle Scholar
  10. 10.
    Nakatsuka K, Nishizawa Y, Hagiwara S, et al. Effect of calcitonin on total body bone mineral contents of experimental os-teoporotic rats determined by dual photon absorptiometry. Calcif Tissue Int 1990 Dec; 47: 378–82PubMedGoogle Scholar
  11. 11.
    Nitta T, Nakamuta H, Hoshino T, et al. Glucocorticoid-induced osteopenia in rats as an osteoporotic model and effect of salmon calcitonin [abstract]. Jpn J Pharmacol 1995; 67 Suppl. 1: 241Google Scholar
  12. 12.
    Robin JC, Ambrus JL. Studies on osteoporosis VI. Effect of human and salmon calcitonin on experimental osteoporosis. Res Commun Chem Pathol Pharmacol 1982 Mar; 35: 491–8PubMedGoogle Scholar
  13. 13.
    Farley JR, Hall SL, Herring S, et al. Two biochemical indices of mouse bone formation are increased, in vivo, in response to calcitonin. Calcif Tissue Int 1992 Jan; 50: 67–73PubMedGoogle Scholar
  14. 14.
    Schipper NGM, Romeijn SG, Verhoef J, et al. Hypocalcemic effect of salmon calcitonin following single and repeated nasal and intravenous administration in young rabbits. Calcif Tissue Int 1994 Jan; 54: 50–5PubMedGoogle Scholar
  15. 15.
    Abbiati G, Arrigoni M, Frignani S, et al. Effect of salmon calcitonin on deoxypyridinoline (Dpyr) urinary excretion in healthy volunteers. Calcif Tissue Int 1994 Nov; 55: 346–8PubMedGoogle Scholar
  16. 16.
    Di Perri T, Laghi Pasini F, Capecchi PL, et al. Pharmacodynam-ics of salmon calcitonin in humans: new markers of pharmacological activity. Eur J Clin Pharmacol 1992; 43: 229–33PubMedGoogle Scholar
  17. 17.
    Fiore CE, Romagnoli A, Foti R, et al. Assessment of the biological activity of synthetic salmon calcitonin by intranasal administration in healthy volunteers. Drugs Exp Clin Res 1991; 17(10-11): 537–42PubMedGoogle Scholar
  18. 18.
    Overgaard K, Agnusdei D, Hansen MA, et al. Dose-response bioactivity and bioavailability of salmon calcitonin in pre-menopausal and postmenopausal women. J Clin Endocrinol Metab 1991; 72: 344–9PubMedGoogle Scholar
  19. 19.
    Thamsborg G, Storm TL, Brinch E, et al. The effect of different doses of nasal salmon calcitonin on plasma cyclic AMP and serum ionized calcium. Calcif Tissue Int 1990 Jan; 46: 5–8PubMedGoogle Scholar
  20. 20.
    Buclin T, Randin JP, Jacquet AF, et al. The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcif Tissue Int 1987; 41: 252–8PubMedGoogle Scholar
  21. 21.
    Reginster JY, Denis D, Albert A. Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (i.m.) or placebo injection in normal subjects. Bone Miner 1987; 2: 133–40PubMedGoogle Scholar
  22. 22.
    Thamsborg G, Skousgaard SG, Daugaard H, et al. Acute effects of nasal salmon calcitonin on calcium and bone metabolism. Calcif Tissue Int 1993 Oct; 53: 232–6PubMedGoogle Scholar
  23. 23.
    Vega E, Gonzalez D, Ghiringhelli G, et al. Acute effect of the intranasal administration of salmon calcitonin in osteoporotic women. Bone Miner 1989 Nov; 7: 267–73PubMedGoogle Scholar
  24. 24.
    Wallach S, Farley JR, Baylink DJ, et al. Effects of calcitonin on bone quality and osteoblastic function. Calcif Tissue Int 1993 May; 52: 335–9PubMedGoogle Scholar
  25. 25.
    Hartwell D, Hassager C, Overgaard K, et al. Vitamin D metabolism in osteoporotic women during treatment with estrogen, an anabolic steroid, or calcitonin. Acta Endocrinol 1990 Jun; 122: 715–21PubMedGoogle Scholar
  26. 26.
    Thamsborg G, Storm TL, Daugaard H, et al. Circulating levels of calciotropic hormones during treatment with nasal salmon calcitonin. Acta Endocrinol 1991 Aug; 125: 127–31PubMedGoogle Scholar
  27. 27.
    Laurian L, Oberman Z, Graf E, et al. Calcitonin induced increase in ACTH, β-endorphin and cortisol secretion. Horm Metab Res 1986 Apr; 18: 268–71PubMedGoogle Scholar
  28. 28.
    Trainer PJ, Kirk JM, McLoughlin L, et al. The effects on anterior pituitary hormone secretion of salmon calcitonin in healthy volunteers. Clin Endocrinol Oxf 1991 Apr; 34: 299–304PubMedGoogle Scholar
  29. 29.
    Brown WR, Fetter AD, Van Ryzin RJ, et al. Proliferative pituitary lesions in rats treated with salmon or porcine calcitonin. Toxicol Pathol 1993; 21_(1): 81–6Google Scholar
  30. 30.
    Hanna FW, Smith DM, Johnston CF, et al. Expression of a novel receptor for the calcitonin peptide family and a salmon calci-tonin-like peptide in the alpha-thyrotropin thyrotroph cell line. Endocrinology 1995 Jun; 136: 2377–82PubMedGoogle Scholar
  31. 31.
    Osamura RY, Murakoshi M, Inada R, et al. Biological aspects of pituitary tumors induced by synthetic salmon calcitonin (TZ-CT) in Sprague-Dawley rats. Immunohistochemical and ultrastructural studies. Acta Pathol Jpn 1992 Jun; 42: 401–7PubMedGoogle Scholar
  32. 32.
    Sandoz Pharmaceuticals Corporation. Calcitonin-salmon nasal spray prescribing information. East Hanover, New Jersey, USA, 1995.Google Scholar
  33. 33.
    Gennari C, Agnusdei D, Gonelli S, et al. Prove farmaco-dinamiche per la valutazione dell’efficacia biologica della calcitonina sintetica di salmone spray nasale. In: Mazzuoli GF, editor. Calcitonin 88.: Esi Stampa Medica, San Donato Milanese, 1989, 48–64, 1989Google Scholar
  34. 34.
    Chambers TJ, Magnus CJ. Calcitonin alters behaviour of isolated osteoclasts. J Pathol 1982; 136: 27–39PubMedGoogle Scholar
  35. 35.
    Chambers TJ, Moore A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab 1983; 57: 819–25PubMedGoogle Scholar
  36. 36.
    Holtrop ME, Raisz LG, Simmons HA. The effects of parathyroid hormone, colchicine, and calcitonin on the ultrastructure and the activity of osteoclasts in organ culture. J Cell Biol 1974 Feb; 60: 346–55PubMedGoogle Scholar
  37. 37.
    Singer FR, Melvin KE, Mills BG. Acute effects of calcitonin on osteoclasts in man. Clin Endocrinol 1976; 5 Suppl: 333S–40SGoogle Scholar
  38. 38.
    Bonucci E, Ballanti P, Ramires PA, et al. Prevention of ovari-ectomy osteopenia in rats after vaginal administration of Hyaff 11 microspheres containing salmon calcitonin. Calcif Tissue Int 1995 Apr; 56: 274–9PubMedGoogle Scholar
  39. 39.
    Feldman RS, Krieger NS, Tashjian Jr AH. Effects of parathyroid hormone and calcitonin on osteoclast formation in vitro. Endocrinology 1980; 107: 1137–43PubMedGoogle Scholar
  40. 40.
    Hedlund T, Hulth A, Johnell O. Early effects of parathormone and calcitonin on the number of osteoclasts and on serum-calcium in rats. Acta Orthop Scand 1983; 54: 802–4PubMedGoogle Scholar
  41. 41.
    Parfitt AM. Effetti della calcitonina sul rimodellamento e la struttura ossea: possibili meccanismi di protezione dalle frat-ture vertebrali. In: Mazzuoli G, Christiansen C, Parfitt AM, et al., editors. Osteoporosi e calcitonina: esperienza clinica internazionale. Milan: Promopharma, 1994: 5–22Google Scholar
  42. 42.
    Goldring SR, Roelke MS, Petrison K, et al. Human giant cell tumors of bone. Identification and characterization of cell types. J Clin Invest 1987; 79: 483–91PubMedGoogle Scholar
  43. 43.
    Nicholson GC, Horton MA, Sexton PM, et al. Calcitonin receptors of human osteoclastoma. Horm Metab Res 1987; 19: 585–9PubMedGoogle Scholar
  44. 44.
    Nicholson CG, Moseley JM, Sexton PM, et al. Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin Invest 1978; 78: 355–60Google Scholar
  45. 45.
    Takahashi N, Yamana H, Yoshiki S, et al. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 1988; 122: 1373–82PubMedGoogle Scholar
  46. 46.
    Minkin C, Reynolds JJ, Copp DH. Inhibitory effect of salmon and other calcitonins on calcium release from mouse bone in vitro. Can J Physiol Pharmacol 1971 Apr; 49: 263–7PubMedGoogle Scholar
  47. 47.
    Marx SJ, Aurbach GD, Gavin III JR, et al. Calcitonin receptors on cultured human lymphocytes. J Biol Chem 1974; 249: 6812–6PubMedGoogle Scholar
  48. 48.
    Moran J, Hunziker W, Fisher J. Calcitonin and calcium iono-phores: cyclic AMP responses in cells of a human lymphoid line. Proc Natl Acad Sci USA 1978; 75: 3984–7PubMedGoogle Scholar
  49. 49.
    Farley JR, Wergedal JE, Hall SL, et al. Calcitonin has direct effects on 3[H]thymidine incorporation and alkaline phos-phatase activity in human osteoblast-line cells. Calcif Tissue Int 1991 May; 48: 297–301PubMedGoogle Scholar
  50. 50.
    Iida-Klein A, Yee DC, Brandli DW, et al. Effects of calcitonin on 3′5′-cyclic adenosine monophosphate and calcium second messenger generation and osteoblast function in UMR 106-06 osteoblast-like cells. Endocrinology 1992; 130: 381–8PubMedGoogle Scholar
  51. 51.
    Gennari C, Toccafondi R, Rotella CM, et al. Salmon calcitonin and cGMP production by human kidney: studies in vivo and in vitro. Calcif Tissue Int 1983 May; 35: 273–8PubMedGoogle Scholar
  52. 52.
    Chiarini P, Matassi L, Fabrizi G. Calcitonin and somatic pain: influence of the hormone on the algogenic component of experimental cantharidin-induced cutaneous inflammation [abstract]. Clin Ter 1978; 86: 451PubMedGoogle Scholar
  53. 53.
    Martin TJ. The therapeutic uses of calcitonin. Scott Med J 1978 Apr; 23: 161–5PubMedGoogle Scholar
  54. 54.
    Braga. Calcitonin and its antinociceptive activity: animal and human investigations 1975-1992. Agents Actions 1994; 41: 121–31PubMedGoogle Scholar
  55. 55.
    Pun KK, Chan LW. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 1989 Mar-Apr; 11: 205–9PubMedGoogle Scholar
  56. 56.
    Franceschini R, Cataldi A, Barreca T, et al. Plasma beta-en-dorphin, ACTH and cortisol secretion in man after nasal spray administration of calcitonin. Eur J Pharmacol 1989; 37: 341–3Google Scholar
  57. 57.
    Vescovi PP, Pedrazzoni M, Gerra G, et al. Salmon calcitonin given by nasal spray or by injection does not increase beta-endorphin levels in normal men. Life Sci 1990; 47_(16): 1469–73Google Scholar
  58. 58.
    Colado MI, Ormazabal MJ, Goicoechea C, et al. Involvement of central serotonergic pathways in analgesia elicited by salmon calcitonin in the mouse. Eur J Pharmacol 1994 Feb 11; 252: 291–7PubMedGoogle Scholar
  59. 59.
    Ormazábal MJ, Goicoechea C, Martín I, et al. Involvement of monoaminergic pathways in analgesia induced by repeated administration of salmon calcitonin [abstract]. Methods Find Exp Clin Pharmacol 1994; 16 Suppl. 1: 77Google Scholar
  60. 60.
    Welch SP, Olson KG. Salmon calcitonin-induced modulation of free intracellular calcium. Pharmacol Biochem Behav 1991 Jul; 39: 641–8PubMedGoogle Scholar
  61. 61.
    Martín MI, Goicoechea C, Colado MI, et al. Analgesic effect of salmon-calcitonin administered by two routes. Effect on morphine analgesia. Eur J Pharmacol 1992 Nov 24; 224: 77–82PubMedGoogle Scholar
  62. 62.
    Martín MI, Goicoechea C, Ormazábal MJ, et al. Analgesic effect of two calcitonins and in vitro interaction with opioids. Gen Pharmacol 1995; 26: 641–7PubMedGoogle Scholar
  63. 63.
    Grauer A, Reinel HH, Ziegler R, et al. Neutralizing antibodies against calcitonin. Horm Metab Res 1993 Sep; 25: 486–8PubMedGoogle Scholar
  64. 64.
    Hosking DJ, Denton LB, Cadge B, et al. Functional significance of antibody formation after long-term salmon calcitonin therapy. Clin Endocrinol Oxf 1979 Mar; 10: 243–52PubMedGoogle Scholar
  65. 65.
    Muff R, Dambacher MA, Fischer JA. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis. Osteoporos Int 1991 Feb; 1: 72–5PubMedGoogle Scholar
  66. 66.
    Reginster JY, Azria M, Gaspar S, et al. The effect of salmon calcitonin on blood-ionized calcium in the presence of anti-salmon calcitonin antibodies (from pagetic patients) in young rabbits. Curr Ther Res 1990 Jun; 47: 1063–72Google Scholar
  67. 67.
    Reginster JY, Gaspar S, Deroisy R, et al. Prevention of osteoporosis with nasal salmon calcitonin — effect of anti-salmon calcitonin antibody formation. Osteoporos Int 1993 Sep; 3: 261–4PubMedGoogle Scholar
  68. 68.
    Singer FR, Aldred JP, Neer RM, et al. An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 1972 Sep; 51: 2331–8PubMedGoogle Scholar
  69. 69.
    Grauer A, Raue F, Schneider H-G, et al. In vitro detection of neutralizing antibodies after treatment of Paget’s disease of bone with nasal salmon calcitonin. J Bone Miner Res 1990; 5: 387–91PubMedGoogle Scholar
  70. 70.
    Levy F, Muff R, Dotti-Sigrist S, et al. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget’s disease. J Clin Endocrinol Metab 1988; 67: 541–5PubMedGoogle Scholar
  71. 71.
    Gennari C, Agnusdei D, Camporeale A. Long term treatment with calcitonin in osteoporosis. Horm Metab Res 1993 Sep; 25: 484–5PubMedGoogle Scholar
  72. 72.
    Takahashi S, Goldring S, Katz M, et al. Downregulation of clacitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest 1995; 95: 167–71PubMedGoogle Scholar
  73. 73.
    Kurose H, Seino Y, Shima M, et al. Intranasal absorption of salmon calcitonin. Calcif Tissue Int 1987 Nov; 41: 249–51PubMedGoogle Scholar
  74. 74.
    Pun KK, Chan LW, Lau P, et al. Absorption of intranasal salmon calcitonin in normal subjects and hypogonadic men. Calcif Tissue Int 1990; 46(2): 130–2PubMedGoogle Scholar
  75. 75.
    Overgaard K, Hansen MA, Jensen SB. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992 Sep 5; 305: 556–61PubMedGoogle Scholar
  76. 76.
    Gennari C, Agnusdei D, Gonnelli S, et al. Pharmacodynamic tests for evaluation of the biological efficacy of synthetic salmon calcitonin nasal spray. In: Mazzuoli GF, editor. New therapeutic perspectives: the nasal spray. Proceedings of the International Symposium on Calcitonin; 1988 Mar 26-27: RomeGoogle Scholar
  77. 77.
    Gennari C, Chierichetti SM, Bigazzi S, et al. Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 1985; 38: 455–64Google Scholar
  78. 78.
    Reginster JY, Meurmans L, Deroisy R, et al. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest 1994 Aug; 24: 565–9PubMedGoogle Scholar
  79. 79.
    Concia E, Cruciani M, Bartucci F, et al. Availability of synthetic salmon calcitonin in tissue fluid after a single intravenous dose. Eur J Clin Pharmacol 1994; 46(4): 371–3PubMedGoogle Scholar
  80. 80.
    Sinigaglia L, Varenna M, Arrigoni M, et al. Comparison of plasma and synovial concentrations of synthetic salmon calcitonin after a single intravenous dose. Eur J Clin Pharmacol 1992 Jul; 43: 101–3PubMedGoogle Scholar
  81. 81.
    Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993 Jun; 94: 646-50Google Scholar
  82. 82.
    Rozenberg S, Vandromme J, Kroll M, et al. Overview of the clinical usefulness of bone mineral measurements in the prevention of postmenopausal osteoporosis. Int J Fertil 1995; 40(1): 12–24Google Scholar
  83. 83.
    Meunier PJ, Gozzo I, Chaumet-Riffaud P, et al. Dose-effect on bone density and parathyroid function of intranasal salmon calcitonin when administered without calcium in postmenopausal women. J Bone Miner Res 1992; 7 Suppl. 1: 330Google Scholar
  84. 84.
    Gennari C, Agnusdei D, Montagnani M, et al. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tissue Int 1992 Apr; 50: 381–3PubMedGoogle Scholar
  85. 85.
    Lyritis GP, Magiasis B, Tsakalakos N. Prevention of bone loss in early nonsurgical and nonosteoporotic high turnover patients with salmon calcitonin: the role of biochemical bone markers in monitoring high turnover patients under calcitonin treatment. Calcif Tissue Int 1995 Jan; 56: 38–41PubMedGoogle Scholar
  86. 86.
    Overgaard K, Riis BJ, Christiansen C, et al. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 1989 Aug 19; 299: 477–9PubMedGoogle Scholar
  87. 87.
    Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int 1994 Aug; 55: 82–6PubMedGoogle Scholar
  88. 88.
    Reginster JY, Denis D, Albert A, et al. 1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1987 Dec 26; 2: 1481–3PubMedGoogle Scholar
  89. 89.
    Reginster JY, Denis D, Deroisy R, et al. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin. J Bone Miner Res 1994 Jan; 9: 69–73PubMedGoogle Scholar
  90. 90.
    Reginster JY, Deroisy R, Lecart MP, et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med 1995 May; 98: 452–8PubMedGoogle Scholar
  91. 91.
    Ellerington MC, Stevenson JC. Prevention of osteoporosis: current recommendations. Drugs Aging 1992; 2(6): 508–17PubMedGoogle Scholar
  92. 92.
    Whittington R, Faulds D. Hormone replacement therapy. Part II: a pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease. PharmacoEconomics 1994; 5(6): 513–54PubMedGoogle Scholar
  93. 93.
    Ferrante B, Isa L, Uderzo A. Observations on bone mineral metabolism in natural and surgery menopause. The effect of synthetic salmon calcitonin and calcium on bone turnover [in Italian]. Minerva Ginecol 1993 Mar; 45: 87–93PubMedGoogle Scholar
  94. 94.
    Fioretti P, Gambacciani M, Taponeco F, et al. Effects of continuous and cyclic nasal calcitonin administration in ovariecto-mized women. Maturitas 1992 Dec; 15: 225–32PubMedGoogle Scholar
  95. 95.
    Polatti F, Zara C. Anti-osteoporotic activity of synthetic salmon calcitonin (injectable and nasal spray), and of a synthetic derivative of eel calcitonin. In: Mazzuoli GF, editor. New therapeutic perspectives: the nasal spray. Proceedings of the International Symposium on Calcitonin; 1988 Mar 26-27; RomeGoogle Scholar
  96. 96.
    Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a World Health Organization Study Group. Geneva: WHO, 1994: 1-25.Google Scholar
  97. 97.
    Maini M, Bozzi M, Brignoli E, et al. Calcitonin nasal spray in osteoporosis: short and long-term effects of various treatment regimes [in Italian]. Minerva Med 1995 Mar; 86: 121–7PubMedGoogle Scholar
  98. 98.
    Balint-Peric LA, Prelevic GM, Beslagic Z, et al. The effect of intranasal salmon calcitonin on biochemical parameters of bone turnover in postmenopausal women. Gynecol Endocrinol 1994 Dec; 8: 241–5PubMedGoogle Scholar
  99. 99.
    Mango D, Ricci S, Manna P, et al. Preventive treatment of cortical bone loss with salmon nasal calcitonin in early postmenopausal women. Minerva Endocrinol 1993 Sep; 18: 115–21PubMedGoogle Scholar
  100. 100.
    Kraenzlin ME, Seibel MJ, Trechsel U, et al. Inhibition of bone turnover by salmon calcitonin in postmenopausal women: maximum effect at eight weeks of treatment [abstract]. Eur J Clin Invest 1994; 24 Suppl. 2: 11Google Scholar
  101. 101.
    Rico H, Hernández ER, Revilla M, et al. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 1992 Feb; 16: 131–8PubMedGoogle Scholar
  102. 102.
    Rico H, Revilla M, Hernández ER. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int 1995 Mar; 56: 181–5PubMedGoogle Scholar
  103. 103.
    Overgaard K, Lindsay R, Christiansen C. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study. Clin Ther 1995 Jul-Aug; 17: 680–5PubMedGoogle Scholar
  104. 104.
    Abellan-Perez M, Bayina-Garcia FJ, Calabozo M, et al. Multi-centre comparative study of synthetic salmon calcitonin administered nasally in the treatment of established postmenopausal osteoporosis [in Spanish]. An Med Interna 1995 Jan; 12: 12–6PubMedGoogle Scholar
  105. 105.
    Anonymous. Sandoz (Basel), Study 522. (Data on file).Google Scholar
  106. 106.
    Beck Jensen J-E, Thamsborg G, Kollerup G, et al. Effect of nasal salmon calcitonin in established osteoporosis [abstract]. Bone 1995 Jan; 16 Suppl.: 198SGoogle Scholar
  107. 107.
    Flicker L, Larkins RG, Hopper JL, et al. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis [abstract]. Bone 1995 Jan; 16 Suppl.: 164Google Scholar
  108. 108.
    Gennari C, Agnusdei D, Camporeale A. Effect of salmon calcitonin nasal spray on bone mass in patients with high turnover osteoporosis. Osteoporos Int 1993; 3 Suppl 1: 208–10PubMedGoogle Scholar
  109. 109.
    Overgaard K, Riis BJ, Christiansen C, et al. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol Oxf 1989 Apr; 30: 435–42PubMedGoogle Scholar
  110. 110.
    Overgaard K, Hansen MA, Nielsen V-AH, et al. Discontinuous calcitonin treatment of established osteoporosis — effects of withdrawal of treatment. Am J Med 1990 Jul; 89: 1–6PubMedGoogle Scholar
  111. 111.
    Overgaard K, Christiansen C. Long-term treatment of established osteoporosis with intranasal calcitonin. Calcif Tissue Int 1991; 49 Suppl: S60–3PubMedGoogle Scholar
  112. 112.
    Thamsborg G, Storm TL, Sykulski R, et al. Effect of different doses of nasal salmon calcitonin on bone mass. Calcif Tissue Int 1991 May; 48: 302–7PubMedGoogle Scholar
  113. 113.
    Agnusdei D, Gonnelli S, Camporeale A, et al. Clinical efficacy of one-year treatment with salmon calcitonin nasal spray in established postmenopausal osteoporosis [in Italian]. Minerva Endocrinol 1989 Jul-Sep; 14: 169–76PubMedGoogle Scholar
  114. 114.
    Nielsen NM, von der Recke P, Hansen MA, et al. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers. Calcif Tissue Int 1994 Jul; 55: 8–11PubMedGoogle Scholar
  115. 115.
    Adami S, Passed M, Ortolani S, et al. Effects of oral alendron-ate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995; 17: 383–90PubMedGoogle Scholar
  116. 116.
    Gonnelli S, Agnusdei D, Palmieri R, et al. Effect of nandrolone decanoate and salmon calcitonin in combination on axial and appendicular bone mass in postmenopausal osteoporosis. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Aalborg, Denmark: Handelstrykkeriet Aalborg ApS, 1990: 1423–5Google Scholar
  117. 117.
    Gennari C. Salmon calcitonin (Miacalcic) nasal spray in prevention and treatment of osteoporosis. Clin Rheumatol 1989 Jun; 8 Suppl 2: 61–5PubMedGoogle Scholar
  118. 118.
    Lyritis GF, Tsakalakos N, Magiasis B, et al. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled study. Calcif Tissue Int 1991; 49: 369–72PubMedGoogle Scholar
  119. 119.
    Foti R, Martorana U, Broggini M. Long-term tolerability of nasal spray formulation of salmon calcitonin. Curr Ther Res 1995 Apr; 56: 429–35Google Scholar
  120. 120.
    Tolino A, Romano L, Ronsini S, et al. Treatment of postmenopausal osteoporosis with salmon calcitonin nasal spray: evaluation by bone mineral content and biochemical patterns. Int J Clin Pharmacol Ther Toxicol 1993 Jul; 31: 358–60PubMedGoogle Scholar
  121. 121.
    Pontiroli AE, Pajetta E, Scaglia L, et al. Analgesic effect of intranasal and intramuscular salmon calcitonin in post-meno-pausal osteoporosis: a double-blind, double-placebo study. Aging Clin Exp Res 1994 Dec; 6: 459–63Google Scholar
  122. 122.
    Wimalawansa SJ. Long- and short-term side effects and safety of calcitonin in man: a prospective study. Calcif Tissue Int 1993 Feb; 52: 90–3PubMedGoogle Scholar
  123. 123.
    Granata Q, Amato A, Salvati R, et al. Activity of salmon calcitonin in senile osteoporosis. Curr Ther Res 1991 May; 49: 784–91Google Scholar
  124. 124.
    Reginster JY, Franchimont P. Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol 1985 Apr-Jun; 3: 155–7PubMedGoogle Scholar
  125. 125.
    Goihman-Yahr M. Disseminated granuloma annulare and intra-nasal calcitonin. Int J Dermatol 1993 Feb; 32: 150PubMedGoogle Scholar
  126. 126.
    Strumia R, Mantovani L. May calcitonin spray cause nasal deformation?. Dermatology 1992; 185(1): 72PubMedGoogle Scholar
  127. 127.
    Dal Negro R, Turco P, Pomari C, et al. Calcitonin nasal spray in patients with chronic asthma: a double-blind crossover study vs placebo. Int J Clin Pharmacol Ther Toxicol 1991; 29: 144–6Google Scholar
  128. 128.
    Passed M, Garibaldi L, Davoli L, et al. Systemic and local tolerance of calcitonin nasal spray. In: Mazzuoli GF, editor. New therapeutic perspectives: the nasal spray. Proceedings of the International Symposium on Calcitonin; 1988 Mar 26-27: RomeGoogle Scholar
  129. 129.
    Gariboldi LM, Bolla I, Baroni MC, et al. Long-term local tolerability of intranasal salmon calcitonin in postmenopausal osteoporosis [in Italian]. Minerva Med 1992 Dec; 83: 827–31PubMedGoogle Scholar
  130. 130.
    Dempster DW, Lindsay R. Pathogenesis of osteoporosis. Lancet 1993 March 27; 341: 797–801PubMedGoogle Scholar
  131. 131.
    Alexandre C. Diagnosis and treatment of osteoporosis. Curr Opin Rheumatol 1995 May; 7: 240–2PubMedGoogle Scholar
  132. 132.
    Melton III LJ, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis. J Bone Miner Res 1992; 7: 1005–10PubMedGoogle Scholar
  133. 133.
    Rungby J, Hermann AP, Mosekilde L. Epidemiology of osteoporosis: implications for drug therapy. Drugs Aging 1995 Jun; 6: 470–8PubMedGoogle Scholar
  134. 134.
    Choice of drugs for postmenopausal osteoporosis. Med Lett Drugs Ther 1992 Oct 30; 34: 101-2Google Scholar
  135. 135.
    Anonymous. Prevention and treatment of postmenopausal osteoporosis. National consensus of the “Belgian Bone Club” —September 1993. Clin Rheumatol 1995; 14 Suppl. 3: 7-8Google Scholar
  136. 136.
    Hernández ER, Seco-Durban C, Revilla M, et al. Evaluation of bone density with peripheral quantitative computed tomography in healthy premenopausal perimenopausal, and postmenopausal women. Age Ageing 1995; 24: 447–50PubMedGoogle Scholar
  137. 137.
    Ogle GD, Allen JR, Humphries IRJ, et al. Body-composition assessment by dual-energy x-ray absorptiometry in subjects aged 4-26 y. Am J Clin Nutr 1995; 61: 746–53PubMedGoogle Scholar
  138. 138.
    Rico H, Revilla M, Hernández ER, et al. Sex differences in the acquisition of total bone mineral mass peak assessed throughout dual-energy X-ray absorptiometry. Calcif Tissue Int 1992; 51: 251–4PubMedGoogle Scholar
  139. 139.
    Rico H, Hernández ER, Seco C, et al. Quantitative peripheral computed tomodensitometric study of cortical and trabecular bone mass in relation with menopause. Maturitas 1994; 18: 183–9PubMedGoogle Scholar
  140. 140.
    Meunier PJ. Calcitonin and bone diseases [letterJ. Lancet 1992 Apr 25; 339: 1065PubMedGoogle Scholar
  141. 141.
    Ryan PJ, Harrison R, Blake GM, et al. Compliance with hormone replacement therapy (HRT) after screening for post menoapusal osteoporosis. Br J Obstet Gynaecol 1992; 99: 325–8PubMedGoogle Scholar
  142. 142.
    Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epi-demiological evidence. Prev Med 1991; 20: 47–63PubMedGoogle Scholar
  143. 143.
    Marsh MS, Stevenson JC, Whitehead MI. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis [letter]. Br J Obstet Gynaecol 1993; 100: 399PubMedGoogle Scholar
  144. 144.
    Cooper C, Aihie A. Osteoporosis: recent advances in pathogen-esis and treatment. Q J Med 1994 Apr; 87: 203–9PubMedGoogle Scholar
  145. 145.
    Seeman E, Tsalamandris C, Bass S, et al. Present and future of osteoporosis therapy. Bone 1995 August; 17(2) Suppl.: 23S–9SPubMedGoogle Scholar
  146. 146.
    Francis RM, Anderson FH, Torgerson DJ. A comparison of the effectiveness and cost of treatment for vertebral fractures in women. Br J Rheumatol 1995; 34: 1167–71PubMedGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Greg L. Plosker
    • 1
  • Donna McTavish
    • 1
  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations